February 2026 in “JEADV Clinical Practice” This review discusses the causes of nail pitting in children and adolescents, noting that while most cases are idiopathic, significant associations exist with conditions like psoriasis, juvenile arthritis, and alopecia areata, among others.
February 2026 in “Indian Journal of Skin Allergy” This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.
February 2026 in “Journal of the American Academy of Dermatology” Managing skin diseases during pregnancy and postpartum requires careful consideration of treatment safety and dosing to protect both mother and baby.
February 2026 in “Journal of Drugs in Dermatology” This case study reports on a 13-year-old male with alopecia totalis who experienced successful hair regrowth after being treated with dupilumab, an interleukin-4 and IL-13 antagonist, suggesting its potential utility in managing alopecia areata in pediatric patients with comorbid atopic dermatitis.
January 2026 in “IECCMEXICO” This review highlights how chronic inflammatory skin disorders like psoriasis and atopic dermatitis may be better understood as manifestations of systemic immune dysregulation rather than just skin issues, suggesting that recognizing these conditions as markers of broader immune imbalance can improve diagnosis and medical education.
January 2026 in “Medicina” This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.
Nutrition plays a key role in managing skin disorders, with specific dietary changes helping improve conditions like acne, dermatitis, psoriasis, alopecia, and skin cancer.
January 2026 in “Clinical Journal for Nurse Practitioners in Women s Health” In this article, it is explored how pregnancy-related physiologic changes can predispose women to dermatologic conditions affecting well-being, and it highlights the critical role of women’s health nurse practitioners in managing these conditions with attention to safety and efficacy in pregnant patients.
January 2026 in “Dermatology Review” In this study, the authors highlighted that celiac disease can have various skin manifestations such as dermatitis herpetiformis and psoriasis, which may precede or occur without digestive symptoms, stressing the importance of screening in patients with unexplained dermatoses.
December 2025 in “International Journal of Innovative Technologies in Social Science” This study found that disruptions in the skin microbiome, known as dysbiosis, play a significant role in various skin conditions, including atopic dermatitis, psoriasis, acne, rosacea, skin cancer, and impaired wound healing, by altering immune responses and barrier functions.
December 2025 in “Gastroenterology Insights” This study found that IBS is positively associated with psoriasis, rosacea, and urticaria, but inversely associated with acne and vitiligo.
December 2025 in “Journal of Inflammation Research” This study highlights ongoing inequities in access and outcomes for inflammatory skin diseases in Latin America and emphasizes the need for regional registries, harmonized clinical guidelines, and policy reforms to improve equitable dermatologic care.
November 2025 in “PLoS ONE” This study found that synthetic RNA and DNA trigger significant increases in certain chemokines in human keratinocytes, predominantly via NF-κB activation, without evidence of alternative splicing, suggesting other regulatory pathways may be involved.
November 2025 in “International Journal of Applied and Experimental Biology” In this review, the authors discussed the potential of hemp in cosmeceutics for skin conditions like acne and dermatitis, emphasizing its therapeutic properties and formulation challenges but noting the need for standardizing cannabinoid content and documenting effectiveness.
October 2025 in “Journal of Investigative Dermatology” This review highlights the critical role of iron in skin functions and suggests potential dermatologic therapies targeting the iron-skin axis.
October 2025 in “Open Repository of the University of Porto (University of Porto)” In this report, the author summarized activities from a six-month internship in community and hospital pharmacy settings, exploring topics like skin microbiome health implications and advancements in antiviral therapy for Hepatitis B and D, highlighting the pharmacist's role in patient care and innovative treatments.
October 2025 in “JEADV Clinical Practice” This paper creatively examines whether the name "Janus" in Janus kinase inhibitors foreshadows their dual role in the treatment of dermatological conditions, drawing parallels to the Roman god Janus's dual nature and influence over beginnings and transitions.
October 2025 in “Pharmaceutics” This study highlights the clinical potential of microneedles as an innovative transdermal drug delivery system for treating various skin diseases with minimal pain and high patient compliance.
October 2025 in “Indian Journal of Paediatric Dermatology” In this case report, a 6-year-old boy with Netherton syndrome was diagnosed using trichoscopy, which revealed characteristic hair shaft abnormalities such as bamboo, golf tee, and matchstick hairs.
September 2025 in “Indian Dermatology Online Journal” This source explores melatonin's roles beyond circadian rhythm regulation, reporting its benefits in skin conditions like dermatitis, melasma, alopecia, psoriasis, and skin aging due to its antioxidant, anti-inflammatory, and immunomodulatory properties, while highlighting the need for more trials on optimal dosing and long-term safety.
September 2025 in “Journal of Skin and Stem Cell” This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.
September 2025 in “Medicine Today and Tomorrow” This analysis reported that exosomes and growth factors show promise in dermatology by activating skin regeneration processes, aiding conditions like atopic dermatitis and hyperpigmentation, though further research is needed to establish standardized protocols and assess long-term effects.
This report describes a case where a patient's rash initially treated as atopic dermatitis with topical steroids was later diagnosed as tinea incognito, an atypical dermatophyte infection that worsened due to steroid use, but was effectively treated with oral and topical antifungals.
This case report of a four-year-old girl with Nicolaides-Baraitser syndrome highlights severe atopic dermatitis and worsening alopecia, suggesting that SMARCA2 dysfunction may impact skin barrier integrity and hair health, necessitating aggressive dermatologic treatment.
This case report details a 47-year-old female with atopic dermatitis who developed alopecia areata after six months on dupilumab therapy; treatment discontinuation and other interventions led to complete hair regrowth, suggesting dupilumab may trigger alopecia areata in patients with atopic or autoimmune predispositions.
July 2025 in “Current Stem Cell Research & Therapy” This analysis found that mesenchymal stem cell-derived exosomes show potential as a safe and effective treatment for various skin and subcutaneous tissue diseases.
June 2025 in “British Journal of Dermatology” In this case report, the temporal relationship between starting dupilumab treatment and the onset of psoriasis in an adult with atopic dermatitis suggests that dupilumab may contribute to psoriatic lesions, and dermatologists should consider psoriasis a potential adverse event of the medication.
June 2025 in “International Journal of Dermatology” This review highlights that exosomes are showing promise as therapeutic, prognostic, and diagnostic agents in dermatology, with clinical studies suggesting efficacy for skin aging, scarring, hair restoration, and inflammatory conditions, though challenges in standardization and regulation remain.
This case study reports that early genetic testing and targeted therapies, such as secukinumab, can significantly improve skin barrier function in patients with Netherton syndrome, despite persistent symptoms.
May 2025 in “International Journal of Trichology” This case report highlights a 7-year-old boy with suspected Netherton syndrome who presented with itchy lesions, hair abnormalities, and elevated immunoglobulin E levels. The authors report complete resolution of symptoms with oral Acitretin after failed methotrexate treatment.